 |
 |
 |
 |
 |
 |
|
|
Heparinex is a biopharmaceutical company focusing on the novel recombinant syntheses of compounds for the growing anticoagulation market, drug development, and associated arenas. The core technology platform was originally discovered and patented by a leading carbohydrate chemist/ glycobiologist at the University of Oklahoma in 2002. Heparinex’s core platforms employ (a) bacterial production techniques and (b) in vitro defined polymer syntheses to provide uniquely controlled non-animal sources of genetically customizable heparinoid compounds for drug discovery, therapeutic formulations and medical device applications. Heparinex is working with our partner Biological E. Ltd. to develop: -Pharmaceutical Anticoagulation Drug Development -Bulk Manufacturing/ Fermentation Processes Heparinex is actively pursuing collaborative partnerships in the following arenas: -Medical Device Coating -Novel Autoimmune/Infectious Disease/ Cancer drug discovery -Enhancing Therapies with Improved PEG Substitute |